

نتقدم بثقة
Moving Forward
with Confidence



To:

Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahda Hospital
Director General of Health Services in all Governorates
Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Health Institutions)
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
The Head of Medical Services in University Medical City
The Head of Medical Services in Medical City for Military and Security Services
Director of Pharmacy of Qaboos Comprehensive Cancer Care & Research Center
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Internal Security Services
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman
All Private Pharmacies & Drug Stores

After Compliments,

Kindly find attached our Circular No 82 dated 19/08/2026 Regarding Update to Health Care Professionals About Domperidone: new contraindication in patients with pheochromocytoma due to the risk of severe hypertension.

Copy to:

- Director of Pharmacovigilance Department, DSC
- Director of Medicine Registration Department, DSC
- Director of Regulatory Compliance Department, DSC
- Director of Central Quality Control Lab., DSC
- Director of Medical Device Department, DSC
- Section Head of Medicine Safety Evaluation
- Section Head of Quality Problems and Medication Errors.
- Section Head of Pharmacovigilance
- Section Head of Clinical Trials



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om



نتقدم بثقة
Moving Forward
with Confidence



Circular No. 82 /2026

06-03-1448 H
19-08-2026

Subject: Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

The Drug Safety Center (DSC) would like to share new safety information published by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding **Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension.**

The product information has been updated for all domperidone products, to include a **contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.**

Domperidone is a dopamine antagonist with anti-emetic properties. It is licensed for use in adults and in children 12 years and above. **Phaeochromocytomas** are rare tumours of the adrenal gland and are often diagnosed through incidental imaging.

Reminder of existing domperidone advice:


- domperidone should be used at the lowest effective dose for the shortest possible duration and maximum treatment duration should **not usually exceed 1 week**
- for adults and adolescents 12 years of age or older and weighing 35 kg or more, the recommended maximum dose in 24 hours is 30 mg (dose interval: 10 mg up to 3 times a day)
- domperidone is authorised for the relief of symptoms of nausea and vomiting only in adults and adolescents 12 years of age or older or weigh 35kg or more
- consider alternative treatments to domperidone in children younger than 12 years of age who need relief of symptoms of nausea and vomiting
- domperidone is contraindicated in people receiving other medications known to prolong QT interval or potent CYP3A4 inhibitors



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om



نقدم بثقة
Moving Forward
With Confidence



Advice for Healthcare Professionals:

- a small number of reports have been received relating to severe episodes of hypertension in patients with pheochromocytoma (a rare tumour of the adrenal gland) following administration of domperidone
- domperidone is now contraindicated in patients with confirmed or suspected pheochromocytoma
- patients with confirmed or suspected pheochromocytoma should stop taking domperidone immediately and be switched to an alternative treatment
- be aware that administration of domperidone can unmask pheochromocytomas. If a patient taking domperidone has an episode of **severe hypertension**, consider further investigations for pheochromocytoma
- domperidone should be used at the **lowest effective dose for the shortest possible duration and maximum treatment duration should not usually exceed 1 week**
- for patients receiving palliative care, an individual benefit risk decision on treatment should be made in discussion with the patient

Advice for Healthcare Professionals to Provide to Patients:

- stop taking domperidone immediately if you have been diagnosed with pheochromocytoma (a rare tumour of the adrenal gland) by your doctor. Speak to your doctor or pharmacist about alternative treatment options
- seek medical attention immediately if you experience symptoms of severe high blood pressure. Symptoms can include, but are not limited to: **persistent headache, blurred vision, shortness of breath and chest pain**

Call to report:

Domperidone is registered in Oman. All healthcare professionals, patients, and caregivers are requested to submit any adverse drug reactions through Ministry of Health e-portal to the Pharmacovigilance Department under the Drug Safety Center.

Dr. Sharifa Amur Al Jabri
Act/ Director General



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
✉ @DSCPHO Email: dscpho@moh.gov.om